Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer
Julie E. Lang(University of Southern California), Laura J. Esserman(University of California, San Francisco), Rita Nanda(University of Chicago), Angela DeMichele(University of Pennsylvania), Denise M. Wolf, Andres Forero‐Torres(Kirklin Clinic), Laura van ‘t Veer, Barbara Haley(Shaanxi Research Association for Women and Family), Bonnie N. Joe(University of California, San Francisco), Erin D. Ellis(University of Hawaii Cancer Center), Adam L. Asare(Quantum Leap Healthcare Collaborative), Scott Berry(Queen's University), Lamorna Brown Swigart(University of California, San Francisco), Emanuel F. Petricoin(Center for Biologics Evaluation and Research), Amy Wilson(Quantum Leap Healthcare Collaborative), Rashmi K. Murthy(The University of Texas MD Anderson Cancer Center), Minetta C. Liu(Mayo Clinic), Qamar J. Khan(University of Kansas Medical Center), Julia Wulfkuhle(University of California, San Francisco), Rachel L. Yung(Seattle Cancer Care Alliance), Ruby Singhrao(University of California, San Francisco), Judy C. Boughey(Mayo Clinic in Arizona), Douglas Yee(University of Minnesota Medical Center), John Park(California Baptist University), Nola M. Hylton(University of California, San Francisco), Julia L. Clennell(Berry & Associates (United States)), Erica Stringer-Reasor(University of Alabama at Birmingham), Smita Asare(Quantum Leap Healthcare Collaborative), Kristen K. Edmiston(Nova Medical (United States)), Meredith Buxton(Center for Effective Global Action), Barbara A. Parker(University of California San Diego), A. Jo Chien(University of California, San Francisco), Hyo S. Han(Moffitt Cancer Center), Kathy S. Albain(Loyola University Chicago), Christina Yau(Hospital Authority), Amy S. Clark(Abramson Center for Jewish Life), Jeffrey B. Matthews(University of California, San Francisco), Claudine Isaacs(Georgetown University), Jane Perlmutter(Gemini Computers (United States)), Donald A. Berry(Berry & Associates (United States)), Elissa R. Price(University of California, San Francisco), Gillian L. Hirst(University of California, San Francisco), Hope S. Rugo(City of Hope), Anne M. Wallace(University of California San Diego), Anthony Elias(University of Colorado Cancer Center), Heather Beckwith(University of Minnesota Medical Center), Michelle Melisko(University of California, San Francisco), Ashish Sanil(Berry & Associates (United States)), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center)
Cited by 27
Related Papers
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
|New England Journal of Medicine|2002|6.5k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k